Assembly BiosciencesASMB +10.25%32 Receivables Turnover is 11.53 as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 846 Biotechnology companies, Assembly Biosciences ranks better than 97.16% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Assembly Biosciences's Revenue for the
three
months ended in Mar. 2026 was $8.21 Mil. Assembly Biosciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.71 Mil.
Hence, Assembly Biosciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 11.53.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Assembly Biosciences Receivables Turnover Related Terms
Assembly Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs CTNM, PRTA, RGNX: Receivables Turnover Comparison
For the Biotechnology subindustry, Assembly Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a Receivables Turnover of 11.53 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #24 out of 846 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Assembly Biosciences' Receivables Turnover too high?
Assembly Biosciences' current Receivables Turnover is 11.53. The Biotechnology industry median Receivables Turnover is 5.29. Assembly Biosciences' value of 11.53 is 118.2% above this industry median. Based on the distribution chart, Assembly Biosciences ranks #24 out of 846 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Receivables Turnover compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #24 out of 846 companies for Receivables Turnover. This places Assembly Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Assembly Biosciences' value of 11.53 is 118.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Receivables Turnover of 11.53 is 118.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Receivables Turnover is 11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Receivables Turnover of 11.53. The current Receivables Turnover is 11.53 and 118.2% above the Biotechnology industry median of 5.29. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Receivables Turnover is 11.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
